Aug 19, 2026 · 7 min
Moderna surges as retailers signal diverging consumer strength
Target Posts Comp Sales Beat, Lowe's Slips on Outlook, Moderna Soars on Melanoma Study
The episode contrasts a major clinical catalyst with uneven retail results, showing how company-specific news and housing weakness are reshaping market expectations.
- 1Moderna shares surged after a personalized cancer vaccine trial with Merck produced a significant breakthrough.
- 2Target beat comparable-sales estimates and raised full-year guidance, yet its stock still declined.
- 3Lowe’s lowered its sales outlook amid a weak housing market, while Estée Lauder benefited from Asia-Pacific growth.
Don't miss
Moderna’s stock surged more than 40% after the reported breakthrough in its personalized cancer vaccine trial with Merck.
The brief
Nathan Hager hosts Bloomberg Radio’s Stock Movers with Bloomberg contributor Dan Curtis, examining the day’s sharpest company-specific market moves.
Moderna surged more than 40% after a significant breakthrough in its personalized cancer vaccine trial with Merck, making clinical progress the episode’s standout catalyst.
Target’s stock declined despite a comparable-sales beat and higher full-year guidance, underscoring how investors can look beyond headline earnings.
Lowe’s lowered its sales outlook as the weak housing market weighed on expectations, while Estée Lauder reported strong quarterly performance driven by Asia-Pacific growth.
Together, the moves show markets separating clinical promise, retail execution, and broader economic exposure rather than rewarding every positive result equally.
What was said on this episode
7 statements · 5 positive · 2 negative
Moderna’s personalized cancer vaccine reduced melanoma recurrence in a late-stage trial.
“Moderna said its personalized cancer vaccine helped cut the recurrence of melanoma in a large late stage trial.”
Listen at 1:21
The vaccine could help prevent melanoma tumors from spreading.
“The study also met a secondary goal, basically showing the shock could help prevent tumors from spreading to new areas of the body.”
Listen at 1:40
Target projects approximately 5% net-sales growth in the current fiscal year.
“the company is projecting net sales to increase about 5% in the current fiscal year.”
Listen at 2:14
Target’s tariff refunds will not provide a long-term benefit.
“Also part of this beat is fueled by tariff refunds. That's not going to be a long term benefit.”
Listen at 2:46
Target is expected to post its first annual net-sales growth since 2022.
“It is seen as posting the first year of net sales growth since 2022.”
Listen at 3:11
Lowe’s discretionary DIY spending pressure offsets growth in pro, online, and home services.
“The company is seeing pressure in its discretionary DIY spending and that's countering growth in its pro online and home services.”
Listen at 3:48
Estée Lauder projects fiscal-2027 EPS above Wall Street expectations.
“Estee Lauder also projecting fiscal year 2027 EPS that point towards a bottom line that will be higher than Wall street was expecting.”
Listen at 4:30
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Lowe's
The Estée Lauder Companies Inc.Listen to the full episode and explore every guest, topic, and moment on PodLume.